Sutro Biopharma STRO Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's net income?
- Sutro Biopharma (STRO) reported net income of -$38.48M in Q1 2026.
- How has Sutro Biopharma's net income changed year-over-year?
- Sutro Biopharma's net income increased by 49.3% year-over-year, from -$75.97M to -$38.48M.
- What is the long-term trend for Sutro Biopharma's net income?
- Over 3 years (2021 to 2025), Sutro Biopharma's net income has grown at a 21.9% compound annual growth rate (CAGR), from -$105.54M to -$191.09M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.